In determining the targeted therapeutic potential of doxycycline in a cohort of GC patients, it was found that doxycycline activates MTF1-mediated transcription and inhibits histones, proteasome genes, fibroblast growth factors, and other oncogenic factors. Here, MTF1 is linked to gastric cancer.